



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

LipidLaunch™ LP-01 LNP (GFP)


Item No. 40100

Overview and Properties

Synonym: LipidLaunch™ CIN-16645 LNP (GFP)
Storage: -80°C (as supplied)
Stability: ≥6 months
Supplied in: TBS, pH 7.5, with 10% sucrose
Ex./Em. Max: 488/507 nm

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Transfection of cells with GFP-encapsulating LP-01 particles. Huh7 hepatocytes (left) and A549 lung epithelial cells (right) were incubated with Cayman's LipidLaunch™ LP-01 LNP (GFP) (Item No. 40100) at an RNA concentration of 250 ng/ml for 24 hours in cell culture media with 10% FBS. Cells were stained with 4 µM Hoechst 33342 (Item No. 15547) and imaged using 465 LED/GFP cube and 365 LED/DAPI cube on a BioTek Cytation 5 imaging plate reader.

LNP Characterization Parameters	
Size	75-150 nm
Polydispersity index (PDI)	<0.2
Encapsulation efficiency (%EE)	>85%
mRNA concentration	Batch specific, 25-100 µg/ml
mRNA/vial	5 µg

Description

LipidLaunch™ LP-01 LNP (GFP) is a solution containing lipid nanoparticles (LNPs) composed of the ionizable cationic amino lipid LP-01 (Item No. 37278), cholesterol (Item Nos. 9003100 | 39088), the phospholipid 1,2-distearoyl-*sn*-glycero-3-PC (DSPC; Item Nos. 15100 | 39189), and the lipid excipient DMG-PEG(2000) (Item No. 33945) at a molar ratio of 45:44:9:2 and encapsulating mRNA encoding the fluorescent protein GFP. It is intended for proof-of-concept experiments to determine whether LP-01-based LNPs can effectively lead to the expression of a protein of interest in a target cell type, either *in vitro* or *in vivo*. GFP displays excitation/emission maxima of 488/507 nm, respectively.

Suggested *in vitro* use: Thaw LNPs on ice with occasional gentle swirling (*do not vortex*). Using a gentle pipetting technique, dilute 1:100-1:500 in complete cell culture media (with serum) and add to subconfluent adherent cells in a fluorescence imaging-compatible tissue culture plate. Expression of GFP may be detectable as early as six hours after treatment. Optimal conditions are highly dependent on cell type.

WARNING
 THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
 This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
 Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/16/2024

CAYMAN CHEMICAL
 1180 EAST ELLSWORTH RD
 ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
 [734] 971-3335
FAX: [734] 971-3640
 CUSTSERV@CAYMANCHEM.COM
 WWW.CAYMANCHEM.COM